Figure 2.
Escalating dose phase I clinical trial of p28 in patients (N=15) with advanced, refractory, p53-positive (>10% cells; IHC) solid tumours.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.